10:08 AM EDT, 03/22/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Friday clinical trials of its investigational drug candidate ivonescimab, alone or combined with chemotherapy, led to intercranial responses among 34% of patients with brain metasteses at baseline, with 23% seeing a complete response, in its treatment for metastatic non-small cell lung cancer.

The biopharmaceutical company reported the findings at the 2024 European Lung Cancer Congress in Prague.

It also said there were no cases of intracranial bleeding observed in patients with brain metastases.

The drug candidate is currently undergoing multiple phase III clinical trials, the company said.

Price: 3.51, Change: -0.04, Percent Change: -1.13